Key facts
- Pattern (Discovery Tools)’s last known valuation is $105.0M (Aug 2025).
- It has raised $92.1M; the latest was Later Stage VC ($44.2M) in Aug 2025.
- Notable investors include Siparex, Illumina Ventures, CoInvest Capital, CARB-X, Concorde Investment Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Pattern (Discovery Tools)
- ·The full record, as it builds
Funding rounds
No funding rounds for Pattern (Discovery Tools) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pattern (Discovery Tools)
Provider of single-cell microbiology antimicrobial treatment intended to simplify antibiotic selection for life-threatening infections. The company includes antibiotic selection through a lab test that uses single-cell analysis technology to shorten test time by zooming in and measuring the live response of each pathogenic cell directly, enabling doctors to improve patient outcomes and slow down the emergence of bacteria that are resistant to existing antibiotics.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2016
- Employees
- 45
- Website
- pattern.bio/
- Ownership
- Privately Held (backing)
Pattern (Discovery Tools) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pattern (Discovery Tools) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pattern (Discovery Tools) in its N-PORT filings yet. We sweep new filings monthly.